July 05, 2026

White Paper on trans gender womens biological estrogen needs

White Paper
Current Evidence on Estrogen Therapy, Neurodevelopment, and Genetics in Transgender Women

by Paula Aurélie Fisher

This educational white paper summarizes themes from the peer-reviewed literature identified in this conversation, these being available as references at the summary of this white paper. It distinguishes established clinical findings from biologically plausible hypotheses and areas of ongoing research.

The primary reason for producing this is quite simple in it's complexity. I know a vast amount of trans-gender women and what is apparent is the simple fact that they function remarkably well on low testosterone and normal female levels of estrogen. A normal biological male on low testosterone exhibits various levels of dysfunction, these obviously include libido, but lethargy too and other mental faculties are significantly impacted.

Trans-gender women on the other hand, excluding the low libido generally do not suffer from any of those issues and mostly seem to thrive on estrogen. Why is this ? Is there some deeper biological nuance we are missing ? Given that the 21^st century has given us a multitude of genetics, neuroscience and the related brain scan studies, all of which significantly indicate the empirical evidence that trans-gender people are in fact born trans-gender, i.e. their incongruence is a genetic event during roughly week 11 and week 19 gestation, therefore given the evidence of a brain cortex developed off of estrogen vs testosterone, then it's feasible then that as an adult, there is a clear need to function with estrogen.

This white paper, while it highlights significant findings supporting estrogen-based trans-gender women with development as such in-utero, there are still much more definitive research that is needed as you can read below, some evidence is modest in the evaluation, but still present and a viable candidate, however in other areas, there is strong supporting evidence.

While I do not have a medical background, I do have expertise in big data and enterprise level systems, meaning I understand data and have the ability to read technical papers. This white paper then is a correlation of multiple medical references from subject matter experts in the field on genetics and neuroscience.

This paper is also the selected evidence related to the below informative graphic …

Executive Summary

Strong clinical evidence indicates that feminizing hormone therapy reduces gender dysphoria and improves quality of life for many transgender women when medically supervised.

Converging evidence from developmental biology, genetics, neuroimaging, endocrinology, and epigenetics supports a prenatal neurodevelopmental contribution to gender identity.

No single gene, receptor, biomarker, or imaging test currently diagnoses gender incongruence or predicts response to estrogen. The available evidence identifies several biologically plausible candidates, but it he picture is of interacting pathways rather than a single receptor defect, I.E. polygenic.

Clinical Evidence

Consistent reductions in gender dysphoria after estrogen-based hormone therapy.

Improvements in anxiety, depression, body congruence, and patient-reported well-being are reported across many studies.

Brain imaging demonstrates hormone-responsive changes in structure and connectivity, although these findings do not provide a causal mechanism. This being a limitation of imaging technology and the associated interpretive software. However the brain imaging aspect of the reference material will not be pertinent to evaluation of genetic hormonal relationships chemically.

Proposed Biological Framework

Polygenic susceptibility involving multiple genes of small effect.
Prenatal hormone signaling, receptor sensitivity, and epigenetic regulation influence fetal brain development.
Brain sexual differentiation occurs after genital differentiation, providing a biologically plausible developmental window for divergence.
Estrogen therapy may provide a more congruent endocrine environment for some transgender women, but receptor-level mechanisms remain under investigation.

Candidate Genes and Biological Pathways

Gene	Primary Role	Research Context
AR	Androgen receptor	Steroid signaling; candidate-gene association studies
ESR1	Estrogen receptor α	Estrogen signaling and neural development
ESR2	Estrogen receptor β	Neuronal maturation and plasticity
CYP19A1	Aromatase	Local estradiol synthesis
CYP17A1	Steroidogenesis	Hormone precursor synthesis
CYP11A1	Steroidogenesis	Initial steroid hormone synthesis
SRD5A2	5α-reductase	Conversion of testosterone to DHT

Medical overview of receptors

1. Estrogen Receptor α (ESR1)

This is one of the strongest candidate receptors.

Function

Nuclear estrogen receptor
Regulates transcription of hundreds of genes
Highly active during fetal brain development
Influences neuronal differentiation and synapse formation

Brain regions

High expression occurs in:

hypothalamus
amygdala
hippocampus
prefrontal cortex

Why it matters

Variants in the ESR1 gene have been reported in some candidate-gene studies of transgender populations. Since ESR1 influences how cells respond to estrogen, differences in receptor expression or function could alter developmental responses to prenatal hormones.

Current evidence: Moderate; associations have been reported, but replication is still needed.

2. Estrogen Receptor β (ESR2)

Another major candidate.

Function

Regulates neuronal maturation
Modulates synaptic plasticity
Influences dendritic spine formation
Has anti-inflammatory and neuroprotective effects

Importance

ESR2 is particularly abundant in cortical and limbic regions involved in cognition and emotion.

Some studies have identified ESR2 variants in transgender cohorts, suggesting it may contribute to susceptibility.

Current evidence: Moderate.

3. Androgen Receptor (AR)

Although not an estrogen receptor, AR is central to the model.

Function

Binds testosterone and dihydrotestosterone (DHT)
Regulates androgen-responsive gene transcription

Relevance

Several studies have examined polymorphisms in the AR gene, including CAG repeat length, which can influence receptor activity. Reduced androgen receptor signaling is one proposed mechanism by which brain development could diverge from genital development.

Current evidence: Moderate, with inconsistent findings across studies.

4. Aromatase (CYP19A1)

Strictly speaking, aromatase is an enzyme rather than a receptor, but it is crucial.

Function

Converts:

testosterone → estradiol

within many tissues, including the brain.

Importance

Local estrogen production in the fetal brain is essential for aspects of sexual differentiation.

Variants affecting aromatase activity could influence the amount of estrogen available to activate ESR1 and ESR2.

Current evidence: Moderate.

5. Steroid Receptor Co-regulators

The receptor itself is only part of the signaling system.

Estrogen receptors recruit proteins such as:

NCOA1 (SRC-1)
NCOA2
NCOA3
NCOR1
NCOR2

These co-activators and co-repressors determine how strongly estrogen-responsive genes are expressed.

These proteins have not been established as markers for gender incongruence, but they are biologically plausible contributors.

Current evidence: Preliminary.

6. Progesterone Receptor (PGR)

Progesterone signaling interacts with estrogen during brain development.

Potential roles include:

neuronal maturation
synaptic organization
myelination

Evidence linking PGR directly to transgender identity is currently limited as far as in-utero development, however it's significant post-natal and has overwhelming evidence to assisting trans-gender women.

7. G Protein-Coupled Estrogen Receptor (GPER1)

Unlike ESR1 and ESR2, which mainly regulate gene transcription, GPER1 mediates rapid, non-genomic estrogen signaling.

Functions include:

intracellular calcium signaling
kinase activation
synaptic modulation

It has been proposed as a candidate in neurodevelopment but has not yet been implicated specifically in transgender cohorts. Although the Kinase activation is a direct contributor to the Cortical Thickness (CTh) Shifts: MRI studies indicate that prior to hormone therapy, untreated trans individuals exhibit unique cerebral patterns. This then collaborates in-utero brain development.

Downstream signaling pathways

When estrogen binds ESR1 or ESR2, it can activate several intracellular pathways involved in neural development:

PI3K–AKT pathway: cell survival and synaptic growth.
MAPK/ERK pathway: neuronal differentiation and plasticity.
CREB signaling: learning, memory, and gene transcription.
BDNF pathway: neuronal survival and synaptic plasticity.

These pathways are well established in neuroscience, although their specific roles in gender identity remain under investigation.

A hypothetical integrated model

One proposed sequence, consistent with the literature but not yet proven, is:

Genetic variants affect steroid hormone receptors and enzymes.
Prenatal hormone signaling differs subtly in the developing brain.
Epigenetic regulation modifies expression of receptor-related genes.
Neural circuits involved in body perception, self-representation, and aspects of sexually dimorphic development are organized differently.
In adulthood, estrogen-based therapy may align more closely with those circuits in some transgender women, contributing to reductions in gender dysphoria and improvements in well-being.

Overall assessment

Among the receptors discussed, ESR1, ESR2, and AR have the strongest support from the candidate-gene literature referenced because they are directly involved in sex steroid signaling and have been investigated in association studies. CYP19A1, CYP17A1, CYP11A1, and SRD5A2 are not receptors but are equally important because they regulate the synthesis and metabolism of the hormones that activate those receptors.

It's important to emphasize that no current study demonstrates that transgender women as a group "process estrogen better" at these receptors than biological women. The evidence supports the hypothesis that inherited variation in these signaling pathways may contribute to prenatal brain development and later hormone responsiveness, but the specific receptor-level mechanisms remain an active area of research rather than an established clinical fact.

Every year there are significant improvements in clinical research, brain scan technology and the associated technological image processing along with research into genetic evaluations.

Evidence Assessment

Strong: clinical benefit of gender-affirming hormone therapy for appropriately selected patients.
Moderate: prenatal neurodevelopmental model integrating genetics, endocrinology, and neuroimaging.
Emerging: specific receptor biology, polygenic architecture, and individualized hormone responsiveness.

Selected Subject Matter Experts (SMEs)

Some of the subject matter experts from the 26 reference studies used to create this white paper.

Researcher	Qualifications	Primary Contribution
J. Graham Theisen	MD; physician-scientist in reproductive endocrinology and infertility	Candidate-gene association studies; polygenic models
Vincent Harley	PhD; molecular geneticist; Hudson Institute	Sex determination genetics; steroid signaling
Julie Bakker	PhD; Professor of Neuroendocrinology	Prenatal hormone biology; brain sexual differentiation
Antonio Guillamon	MD, PhD; Professor Emeritus of Psychobiology	Neurodevelopment; neuroanatomy
Ivanka Savic	MD, PhD; Professor of Neurology	Functional neuroimaging; neuroendocrinology
Dick F. Swaab	MD, PhD; neuroscientist	Hypothalamic development; BSTc research
Alicia Garcia-Falgueras	PhD; neuroscientist	Sexually dimorphic brain structures
William Reiner	MD; pediatric urologist and academic physician	Disorders of sex development; gender development
Peggy T. Cohen-Kettenis	PhD; clinical psychologist and researcher	Developmental and longitudinal gender identity research

Limitations

Most genetic findings are candidate-gene associations with modest effect sizes
Replication across larger and more diverse cohorts remains necessary
Association does not yet establish a concise causation and remains polygenic
Clinical decisions should follow established professional guidelines and individualized assessment
While limitations exist, it does not preclude solid hypothesis related to the results

Conclusion

The current literature supports a biologically plausible model in which genetics, prenatal hormone signaling, epigenetic regulation, and fetal brain development interact to influence gender identity. Estrogen therapy has strong evidence for improving gender dysphoria and quality of life in many transgender women, the evidence therefore supports the hypothesis that inherited variation in these signaling pathways may contribute to prenatal brain development and later hormone responsiveness in trans-gender women, verses the reliance solely on testosterone. While the precise molecular mechanisms underlying differential hormone responsiveness remain an active area of investigation.